| MIRD pamphlet no. 21: a generalized schema for radiopharmaceutical dosimetry—standardization of nomenclature WE Bolch, KF Eckerman, G Sgouros, SR Thomas Journal of Nuclear Medicine 50 (3), 477-484, 2009 | 914 | 2009 |
| Targeted α particle immunotherapy for myeloid leukemia JG Jurcic, SM Larson, G Sgouros, MR McDevitt, RD Finn, CR Divgi, ... Blood, The Journal of the American Society of Hematology 100 (4), 1233-1239, 2002 | 596 | 2002 |
| Radioimmunotherapy with alpha-emitting nuclides MR McDevitt, G Sgouros, RD Finn, JL Humm, JG Jurcic, SM Larson, ... European journal of nuclear medicine 25, 1341-1351, 1998 | 534 | 1998 |
| Radiopharmaceutical therapy in cancer: clinical advances and challenges G Sgouros, L Bodei, MR McDevitt, JR Nedrow Nature reviews Drug discovery 19 (9), 589-608, 2020 | 514 | 2020 |
| MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy G Sgouros, JC Roeske, MR McDevitt, S Palm, BJ Allen, DR Fisher, ... Journal of nuclear medicine 51 (2), 311-328, 2010 | 497 | 2010 |
| Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ... Molecular imaging and biology 17, 565-574, 2015 | 493 | 2015 |
| Prognostic Value of[ 18F]Fluorodeoxyglucose Positron Emission Tomographic Scanning in Patients with Thyroid Cancer W Wang, SM Larson, M Fazzari, SK Tickoo, K Kolbert, G Sgouros, ... The Journal of Clinical Endocrinology & Metabolism 85 (3), 1107-1113, 2000 | 437 | 2000 |
| MIRD pamphlet no. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy YK Dewaraja, EC Frey, G Sgouros, AB Brill, P Roberson, PB Zanzonico, ... Journal of Nuclear Medicine 53 (8), 1310-1325, 2012 | 434 | 2012 |
| 2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate … Y Chen, M Pullambhatla, CA Foss, Y Byun, S Nimmagadda, ... Clinical cancer research 17 (24), 7645-7653, 2011 | 415 | 2011 |
| Bone marrow dosimetry for radioimmunotherapy: theoretical considerations G Sgouros Journal of Nuclear Medicine 34 (4), 689-694, 1993 | 396 | 1993 |
| Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software G Sgouros, KS Kolbert, A Sheikh, KS Pentlow, EF Mun, A Barth, ... Journal of Nuclear Medicine 45 (8), 1366-1372, 2004 | 383 | 2004 |
| Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic … SY Cho, KL Gage, RC Mease, S Senthamizhchelvan, DP Holt, ... Journal of Nuclear Medicine 53 (12), 1883-1891, 2012 | 330 | 2012 |
| An α-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer MR McDevitt, E Barendswaard, D Ma, L Lai, MJ Curcio, G Sgouros, ... Cancer research 60 (21), 6095-6100, 2000 | 325 | 2000 |
| N-[N-[(S)-1, 3-Dicarboxypropyl] carbamoyl]-4-[18F] fluorobenzyl-L-cysteine,[18F] DCFBC: a new imaging probe for prostate cancer RC Mease, CL Dusich, CA Foss, HT Ravert, RF Dannals, J Seidel, ... Clinical Cancer Research 14 (10), 3036-3043, 2008 | 316 | 2008 |
| Sequential cytarabine and α-particle immunotherapy with bismuth-213–lintuzumab (HuM195) for acute myeloid leukemia TL Rosenblat, MR McDevitt, DA Mulford, N Pandit-Taskar, CR Divgi, ... Clinical cancer research 16 (21), 5303-5311, 2010 | 302 | 2010 |
| Pharmacokinetics and dosimetry of an α-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia G Sgouros, ÅM Ballangrud, JG Jurcic, MR McDevitt, JL Humm, YE Erdi, ... Journal of Nuclear Medicine 40 (11), 1935-1946, 1999 | 280 | 1999 |
| MIRD pamphlet no. 20: the effect of model assumptions on kidney dosimetry and response—implications for radionuclide therapy BW Wessels, MW Konijnenberg, RG Dale, HB Breitz, M Cremonesi, ... Journal of Nuclear Medicine 49 (11), 1884-1899, 2008 | 221 | 2008 |
| A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity PC Caron, JG Jurcic, AM Scott, RD Finn, CR Divgi, MC Graham, ... | 213 | 1994 |
| Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. CR Divgi, NH Bander, AM Scott, JA O'Donoghue, G Sgouros, S Welt, ... Clinical cancer research: an official journal of the American Association …, 1998 | 204 | 1998 |
| MIRD pamphlet no. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney LG Bouchet, WE Bolch, HP Blanco, BW Wessels, JA Siegel, DA Rajon, ... Journal of Nuclear Medicine 44 (7), 1113-1147, 2003 | 198 | 2003 |
